Patent ReferencesFLK-1 is a receptor for vascular endothelial growth factor DNA vaccination for induction of suppressive T cell response Bi-functional plasmid that can act as both a DNA vaccine and a recombinant virus vector Patent #: 6086891 InventorsApplicationNo. 10090183 filed on 03/02/2002US Classes:424/200.1, Recombinant or stably-transformed bacterium encoding one or more heterologous proteins or fragments thereof424/185.1, Amino acid sequence disclosed in whole or in part; or conjugate, complex, or fusion protein or fusion polypeptide including the same424/93.1, WHOLE LIVE MICRO-ORGANISM, CELL, OR VIRUS CONTAINING424/93.2, Genetically modified micro-organism, cell, or virus (e.g., transformed, fused, hybrid, etc.)424/93.4, Bacteria or actinomycetales435/252.3Transformants (e.g., recombinant DNA or vector or foreign or exogenous gene containing, fused bacteria, etc.)ExaminersPrimary: Priebe, Scott D.Assistant: Burkhart, Michael Attorney, Agent or FirmForeign Patent References
International ClassesA61K 39/00A61K 48/00 C12N 1/21 A01N 63/00 AbstractA DNA vaccine effective for inhibiting endothelial cell proliferation comprises a DNA construct operably encoding a vascular endothelial growth factor (VEGF) receptor protein. This invention provides DNA vaccines that encode VEGF receptor-2 (KDR, SEQ ID NO: 2), VEGF receptor-1 (Flt-1, (SEQ ID NO: 4), or Flk-1 (the murine homolog of KDR, SEQ ID NO: 6), DNA sequences SEQ ID NOS: 1, 3, and 5 respectively, as well as methods of using such a DNA vaccine to inhibit vascular endothelial cell proliferation in the tumor micro-environment. Anti-angiogenesis and subsequent decrease in tumor growth and dissemination is achieved.Other References
|
| ||||||||||||||